577 related articles for article (PubMed ID: 27296321)
1. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Bracaglia C; de Graaf K; Pires Marafon D; Guilhot F; Ferlin W; Prencipe G; Caiello I; Davì S; Schulert G; Ravelli A; Grom AA; de Min C; De Benedetti F
Ann Rheum Dis; 2017 Jan; 76(1):166-172. PubMed ID: 27296321
[TBL] [Abstract][Full Text] [Related]
2. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.
Put K; Avau A; Brisse E; Mitera T; Put S; Proost P; Bader-Meunier B; Westhovens R; Van den Eynde BJ; Orabona C; Fallarino F; De Somer L; Tousseyn T; Quartier P; Wouters C; Matthys P
Rheumatology (Oxford); 2015 Aug; 54(8):1507-17. PubMed ID: 25767156
[TBL] [Abstract][Full Text] [Related]
3. Sudden Hypotension and Increased Serum Interferon-γ and Interleukin-10 Predict Early Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis.
Guo L; Xu Y; Qian X; Zou L; Zheng R; Teng L; Zheng Q; Leung Jung LK; Lu M
J Pediatr; 2021 Aug; 235():203-211.e3. PubMed ID: 33581106
[TBL] [Abstract][Full Text] [Related]
4. An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
Arduini A; Marasco E; Marucci G; Pardeo M; Insalaco A; Caiello I; Moneta GM; Prencipe G; De Benedetti F; Bracaglia C
Pediatr Rheumatol Online J; 2019 May; 17(1):25. PubMed ID: 31118063
[TBL] [Abstract][Full Text] [Related]
5. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Lee PY; Schulert GS; Canna SW; Huang Y; Sundel J; Li Y; Hoyt KJ; Blaustein RB; Wactor A; Do T; Halyabar O; Chang MH; Dedeoglu F; Case SM; Meidan E; Lo MS; Sundel RP; Richardson ET; Newburger JW; Hershfield MS; Son MB; Henderson LA; Nigrovic PA
Ann Rheum Dis; 2020 Feb; 79(2):225-231. PubMed ID: 31707357
[TBL] [Abstract][Full Text] [Related]
6. Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome.
Bracaglia C; Prencipe G; De Benedetti F
Pediatr Rheumatol Online J; 2017 Jan; 15(1):5. PubMed ID: 28095869
[TBL] [Abstract][Full Text] [Related]
7. Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.
Naveen R; Jain A; Muhammed H; Gupta L; Misra DP; Lawrence A; Agarwal V; Misra R; Aggarwal A
Rheumatol Int; 2021 Mar; 41(3):625-631. PubMed ID: 33388903
[TBL] [Abstract][Full Text] [Related]
8. Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.
Huang S; Liu Y; Yan W; Zhang T; Wang P; Zhu M; Zhang X; Zhou P; Fan Z; Yu H
Pediatr Rheumatol Online J; 2024 May; 22(1):58. PubMed ID: 38783316
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis.
Brossard P; Laveille C
Rheumatol Ther; 2024 Jun; 11(3):869-880. PubMed ID: 38662147
[TBL] [Abstract][Full Text] [Related]
10. Performance of interferon-gamma levels may lead to earlier diagnosing macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
Lu M; Teng L; Xu Y; Xu X
Pediatr Rheumatol Online J; 2023 Oct; 21(1):115. PubMed ID: 37828529
[TBL] [Abstract][Full Text] [Related]
11. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
Yasin S; Fall N; Brown RA; Henderlight M; Canna SW; Girard-Guyonvarc'h C; Gabay C; Grom AA; Schulert GS
Rheumatology (Oxford); 2020 Feb; 59(2):361-366. PubMed ID: 31326996
[TBL] [Abstract][Full Text] [Related]
12. Monocytes From Patients With Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Are Hyperresponsive to Interferon Gamma.
Pascarella A; Bracaglia C; Caiello I; Arduini A; Moneta GM; Rossi MN; Matteo V; Pardeo M; De Benedetti F; Prencipe G
Front Immunol; 2021; 12():663329. PubMed ID: 33815425
[TBL] [Abstract][Full Text] [Related]
13. A dysregulated interleukin-18-interferon-γ-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis.
Hinze T; Kessel C; Hinze CH; Seibert J; Gram H; Foell D
Rheumatology (Oxford); 2021 Nov; 60(11):5165-5174. PubMed ID: 33576397
[TBL] [Abstract][Full Text] [Related]
14. Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome.
Schulert GS; Pickering AV; Do T; Dhakal S; Fall N; Schnell D; Medvedovic M; Salomonis N; Thornton S; Grom AA
Ann Rheum Dis; 2021 May; 80(5):617-625. PubMed ID: 33277241
[TBL] [Abstract][Full Text] [Related]
15. Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Gorelik M; Fall N; Altaye M; Barnes MG; Thompson SD; Grom AA; Hirsch R
J Rheumatol; 2013 Jul; 40(7):1191-9. PubMed ID: 23678162
[TBL] [Abstract][Full Text] [Related]
16. Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.
Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Yachie A
Clin Exp Immunol; 2018 Mar; 191(3):349-355. PubMed ID: 28815559
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome.
Prencipe G; Caiello I; Pascarella A; Grom AA; Bracaglia C; Chatel L; Ferlin WG; Marasco E; Strippoli R; de Min C; De Benedetti F
J Allergy Clin Immunol; 2018 Apr; 141(4):1439-1449. PubMed ID: 28807602
[TBL] [Abstract][Full Text] [Related]
18. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
Schulert GS; Yasin S; Carey B; Chalk C; Do T; Schapiro AH; Husami A; Watts A; Brunner HI; Huggins J; Mellins ED; Morgan EM; Ting T; Trapnell BC; Wikenheiser-Brokamp KA; Towe C; Grom AA
Arthritis Rheumatol; 2019 Nov; 71(11):1943-1954. PubMed ID: 31379071
[TBL] [Abstract][Full Text] [Related]
19. Systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome due to a CASP1 variant causing inflammasome hyperactivation.
Jørgensen SE; Christiansen M; Høst C; Glerup M; Mahler B; Lausten MM; Gad HH; Hartmann R; Herlin T; Mogensen TH
Rheumatology (Oxford); 2020 Oct; 59(10):3099-3105. PubMed ID: 32556329
[TBL] [Abstract][Full Text] [Related]
20. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
Put K; Brisse E; Avau A; Imbrechts M; Mitera T; Janssens R; Proost P; Fallarino F; Wouters CH; Matthys P
PLoS One; 2016; 11(2):e0150075. PubMed ID: 26914138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
